187 related articles for article (PubMed ID: 19694703)
1. Osteopontin expression correlates with invasiveness in cervical cancer.
Song JY; Lee JK; Lee NW; Yeom BW; Kim SH; Lee KW
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):434-8. PubMed ID: 19694703
[TBL] [Abstract][Full Text] [Related]
2. [Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues].
Liu R; Pu DM; Cheng YX; Yin L
Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1326-9. PubMed ID: 17727777
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers.
Sakaguchi H; Fujimoto J; Hong BL; Tamaya T
Cancer Lett; 2007 Mar; 247(1):98-102. PubMed ID: 16675104
[TBL] [Abstract][Full Text] [Related]
4. Expression of tenascin in human cervical cancer--association of tenascin expression with clinicopathological parameters.
Pilch H; Schäffer U; Schlenger K; Lautz A; Tanner B; Höckel M; Knapstein PG
Gynecol Oncol; 1999 Jun; 73(3):415-21. PubMed ID: 10366470
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array.
Wang PH; Ko JL; Tsai HT; Yang SF; Han CP; Lin LY; Chen GD
Gynecol Oncol; 2008 Mar; 108(3):533-42. PubMed ID: 18177928
[TBL] [Abstract][Full Text] [Related]
6. High expression of human nonmetastatic clone 23 type 1 in cancer of uterine cervix and its association with poor cell differentiation and worse overall survival.
Hsu CG; Lin LY; Ko JL; Yang SF; Chang H; Lin CY; Tsai HT; Chen SC; Chen SC; Wang PH
J Surg Oncol; 2008 Nov; 98(6):448-56. PubMed ID: 18668641
[TBL] [Abstract][Full Text] [Related]
7. Correlation of inhibitor of differentiation 1 expression to tumor progression, poor differentiation and aggressive behaviors in cervical carcinoma.
Li J; Jia H; Xie L; Wang X; He H; Lin Y; Hu L
Gynecol Oncol; 2009 Jul; 114(1):89-93. PubMed ID: 19359031
[TBL] [Abstract][Full Text] [Related]
8. Invasive potency related to RCAS1 expression in uterine cervical cancer.
Sonoda K; Miyamoto S; Hirakawa T; Yagi H; Yotsumoto F; Nakashima M; Watanabe T; Nakano H
Gynecol Oncol; 2005 Oct; 99(1):189-98. PubMed ID: 16112176
[TBL] [Abstract][Full Text] [Related]
9. Pitfalls in immunohistochemical validation of tumor marker expression--exemplified in invasive cancer of the uterine cervix.
Hellberg D; Tot T; Stendahl U
Gynecol Oncol; 2009 Jan; 112(1):235-40. PubMed ID: 18976801
[TBL] [Abstract][Full Text] [Related]
10. Nucleoporin 88 expression in normal and neoplastic squamous epithelia of the uterine cervix.
Brustmann H; Hager M
Ann Diagn Pathol; 2009 Oct; 13(5):303-7. PubMed ID: 19751906
[TBL] [Abstract][Full Text] [Related]
11. Expression of Sox2 in human cervical carcinogenesis.
Ji J; Zheng PS
Hum Pathol; 2010 Oct; 41(10):1438-47. PubMed ID: 20709360
[TBL] [Abstract][Full Text] [Related]
12. Parafibromin expression in breast cancer: a novel marker for prognostication?
Selvarajan S; Sii LH; Lee A; Yip G; Bay BH; Tan MH; Teh BT; Tan PH
J Clin Pathol; 2008 Jan; 61(1):64-7. PubMed ID: 17468290
[TBL] [Abstract][Full Text] [Related]
13. The possible role of Bcl-2 expression of tumors of the uterine cervix.
Protrka Z; Djurić J; Protrka O; Arsenijević S
J BUON; 2010; 15(2):323-9. PubMed ID: 20658730
[TBL] [Abstract][Full Text] [Related]
14. Early stromal invasion in cervical cancer: immunocytochemical changes occurring in infiltrating neoplastic cells.
Tarocco E; Mariuzzi L; Bettini R; Bartels PH; Mariuzzi G
Adv Clin Path; 2001 Oct; 5(4):133-8. PubMed ID: 17582937
[TBL] [Abstract][Full Text] [Related]
15. [Cell differentiation during carcinogenesis of cervical epithelia].
Sun Y; Cao YW; Lu TC; Pan XL; Li F; Su L; Jiang JF; Chang B
Ai Zheng; 2005 Oct; 24(10):1184-90. PubMed ID: 16219130
[TBL] [Abstract][Full Text] [Related]
16. Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation.
Sánchez-Hernández PE; Ramirez-Dueñas MG; Albarran-Somoza B; García-Iglesias T; del Toro-Arreola A; Franco-Topete R; Daneri-Navarro A
Gynecol Oncol; 2008 Jan; 108(1):19-26. PubMed ID: 17936340
[TBL] [Abstract][Full Text] [Related]
17. Activation of invasiveness of cervical carcinoma cells by angiotensin II.
Kikkawa F; Mizuno M; Shibata K; Kajiyama H; Morita T; Ino K; Nomura S; Mizutani S
Am J Obstet Gynecol; 2004 May; 190(5):1258-63. PubMed ID: 15167827
[TBL] [Abstract][Full Text] [Related]
18. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication.
Yu W; Liu J; Xiong X; Ai Y; Wang H
Pathol Res Pract; 2009; 205(10):709-15. PubMed ID: 19541433
[TBL] [Abstract][Full Text] [Related]
19. [Serum galectin-9 in cervical cancer].
Liang MY; Lu YM; Zhang Y; Zhang SL
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2783-5. PubMed ID: 19080456
[TBL] [Abstract][Full Text] [Related]
20. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.
Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
Int J Urol; 2009 Mar; 16(3):293-8. PubMed ID: 19207607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
